Printer Friendly

Printed from http://www.researchandmarkets.com/reports/2075502

Acute Coronary Syndrome - Pipeline Review, H1 2012

Description:

Acute Coronary Syndrome – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Acute Coronary Syndrome - Pipeline Review, H1 2012', provides an overview of the Acute Coronary Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Acute Coronary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome. 'Acute Coronary Syndrome - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acute Coronary Syndrome.
- A review of the Acute Coronary Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acute Coronary Syndrome pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Acute Coronary Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acute Coronary Syndrome pipeline depth and focus of Acute Coronary Syndrome therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Acute Coronary Syndrome Therapeutic Products under Development, Key Players in Acute Coronary Syndrome Therapeutics, Acute Coronary Syndrome Pipeline Overview, Acute Coronary Syndrome Pipeline, Acute Coronary Syndrome Pipeline Assessment

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acute Coronary Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for Acute Coronary Syndrome
Acute Coronary Syndrome Therapeutics under Development by Companies
Acute Coronary Syndrome Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Acute Coronary Syndrome Therapeutics – Products under Development by Companies
Acute Coronary Syndrome Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Acute Coronary Syndrome Therapeutics Development
F. Hoffmann-La Roche Ltd.
Sanofi-Aventis
AstraZeneca PLC
GlaxoSmithKline plc
Daiichi Sankyo Company, Ltd
Ablynx
Eisai Co., Ltd.
Glenmark Pharmaceuticals Ltd.
Japan Tobacco Inc.
Bayer AG
Momenta Pharmaceuticals, Inc.
CSL Limited
BioInvent International AB
Resverlogix Corp.
Viron Therapeutics, Inc.
Regado Biosciences.
Cerenis Therapeutics SA
VIA Pharmaceuticals, Inc.
Anthera Pharmaceuticals‚ Inc.
Athera Biotechnologies AB
Lacer, S.A.
Acute Coronary Syndrome – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
E5555 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BAY 81-8781 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BI-204 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Otamixaban - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Darapladib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JTT705 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xarelto - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xarelto - Drug Profile
Product Description
Mechanism of Action
R&D Progress
M118 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VT-111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VIA-2291 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
REG1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
REG-Anti Platelet Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RVX-208 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALX-0081 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cangrelor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BQ123 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CSL112 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hemopure - Drug Profile
Product Description
Mechanism of Action
R&D Progress
A-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RG1512 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDCO-216 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Effient - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CER-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Heme Arginate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prasugrel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Human Atrial Natriuretic Peptide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GBR 600 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Red Blood Cell Transfusion - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clopidogrel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adenocor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Champix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GIK + Intensive Insulin Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RVX-408 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
A-002 + Lipitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Annexin A5 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PC-mAb - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MEDI2338 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LA-8045 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acute Coronary Syndrome Therapeutics – Drug Profile Updates
Acute Coronary Syndrome Therapeutics – Discontinued Products
Acute Coronary Syndrome Therapeutics - Dormant Products
Acute Coronary Syndrome – Product Development Milestones
Featured News & Press Releases
Jan 31, 2012: Daiichi Sankyo Provides Update On Current Status Of Prasugrel Clinical Trials
Jan 24, 2012: Bristol-Myers Squibb And Sanofi Introduce Patient Benefit Program For Plavix
Jan 17, 2012: The Medicines Company Announces Publication Of Clinical Trial Results Of Cangrelor Bridge Trial In Journal Of American Medical Association
Jan 09, 2012: Dabigatran Associated With Increased Risk Of Acute Coronary Events
Dec 22, 2011: Bayer Submits Marketing Authorization Application To EMA For Xarelto
Dec 15, 2011: G-BA Issues Positive Final Medical Benefit Assessment For BRILIQUE In Germany
Dec 14, 2011: Anthera Announces Completion Of Safety Review By DSMB For VISTA-16
Nov 16, 2011: New Analysis Of Data Presented At AHA Shows Effects Of Effient On Cardiovascular Events In STEMI Patients
Nov 16, 2011: Triple-Dose Clopidogrel Can Work In People With Genetic Resistance To It, Study Finds
Nov 13, 2011: New Anti-Clotting Drug Fails To Meet Expectations In Major Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Acute Coronary Syndrome, H1 2012
Products under Development for Acute Coronary Syndrome – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
Sanofi-Aventis, H1 2012
AstraZeneca PLC, H1 2012
GlaxoSmithKline plc, H1 2012
Daiichi Sankyo Company, Ltd, H1 2012
Ablynx, H1 2012
Eisai Co., Ltd., H1 2012
Glenmark Pharmaceuticals Ltd., H1 2012
Japan Tobacco Inc., H1 2012
Bayer AG, H1 2012
Momenta Pharmaceuticals, Inc., H1 2012
CSL Limited, H1 2012
BioInvent International AB, H1 2012
Resverlogix Corp., H1 2012
Viron Therapeutics, Inc., H1 2012
Regado Biosciences., H1 2012
Cerenis Therapeutics SA, H1 2012
VIA Pharmaceuticals, Inc., H1 2012
Anthera Pharmaceuticals‚ Inc., H1 2012
Athera Biotechnologies AB, H1 2012
Lacer, S.A., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Acute Coronary Syndrome Therapeutics – Drug Profile Updates
Acute Coronary Syndrome Therapeutics – Discontinued Products
Acute Coronary Syndrome Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Acute Coronary Syndrome, H1 2012
Products under Development for Acute Coronary Syndrome – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2

Printed Thursday, May 23, 2013
8:48:45 AM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Acute Coronary Syndrome - Pipeline Review, H1 2012

Web Address

http://www.researchandmarkets.com/reports/2075502

Office Code

OC8DIQSOPSNPRU

Report Formats

Please enter the quantity of the report format you require.

Format	Quantity	Price
Electronic (PDF) - Single User		EURO€ 384.00
Electronic (PDF) - Site License		EURO€ 769.00
Electronic (PDF) - Enterprisewide		EURO€ 1,153.00

Contact information

Please enter all the information below in block capitals.

                Title:
            
                    Mr
                    
                    Mrs
                    
                    Dr
                    
                    Miss
                    
                    Ms
                    
                    Prof
                    
                First Name:
            
                Last Name:
                
                Email Address:
            
                Job Title:
            
                Organisation:
            
                Address:
            
                City:
            
                Postal / Zip Code:	
            
                Country:	
            
                Phone Number:	
            
                Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2

Printed Thursday, May 23, 2013
8:48:45 AM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:

Cardholder's Signature:

Expiry Date:

Card Number:

CVV Security Code:

Issue date:

(Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:

Account Number:

83313083

Sort Code:

98-53-30

Swift Code:

ULSBIE2D

IBAN Number:

IE78ULSB98533083313083

Bank Address:

Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Printer Friendly

Acute Coronary Syndrome - Pipeline Review, H1 2012

Fax order form

Order information

Product name

Web Address

Office Code

Report Formats

Contact information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Payment information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)